Recent advancements in canine cancer treatment offer the potential for better outcomes, especially the advancements in immunotherapy treatments. A discussion of the ELIAS cancer immunotherapy (ECI®) for the treatment of canine osteosarcoma in Clinician’s Brief pointed out that “ECI is the only 2-step immunotherapy in veterinary medicine that has the potential to match or exceed the current standard of care while reducing or eliminating the need for chemotherapy.”
The article, “Osteosarcoma Immunotherapy for More Days at Home,” discusses the evidence-based science behind ECI, the potential benefits over chemotherapy, and how referring veterinarians play an active and vital role in the care continuum.
Read the full article at Clinician’s Brief online.